Phase III Trials Begin for Boehringer's Hepatitis C Drug
Share
Follow Us
The Editors at Hepatitis Central
May 3, 2011
Enrolling 1,875 patients with chronic genotype-1 Hepatitis C, Boehringer will begin three phase III trials for BI 201335, an oral protease inhibitor.
Boehringer begins late-stage hep C trial
4/27/11
Boehringer Ingelheim has begun enrolling patients in North America for a phase III trial of its chronic hepatitis C virus (HCV) candidate, which already has fast track designation from US regulators.
BI 201335 is an oral protease inhibitor and will be tested with standard-of-care in both treatment-naive and treatment -experienced patients with chronic genotype-1 HCV.
Continue reading this entire article:
http://www.inpharm.com/news/155103/boehringer-bi-201335-hepatitis-c-trial
